Ernexa Therapeutics Inc.
ERNA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $582 | $68 | $0 | $0 |
| % Growth | 755.9% | – | – | – |
| Cost of Goods Sold | $96 | $236 | $0 | $0 |
| Gross Profit | $486 | -$168 | $0 | $0 |
| % Margin | 83.5% | -247.1% | – | – |
| R&D Expenses | $4,604 | $5,920 | $10,392 | $12,705 |
| G&A Expenses | $13,132 | $14,586 | $16,555 | $14,724 |
| SG&A Expenses | $13,132 | $14,586 | $16,555 | $14,724 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,576 | $461 | $6,270 | $86,303 |
| Operating Expenses | $16,160 | $20,967 | $33,217 | $113,732 |
| Operating Income | -$15,674 | -$21,135 | -$33,217 | -$113,732 |
| % Margin | -2,693.1% | -31,080.9% | – | – |
| Other Income/Exp. Net | -$28,835 | -$536 | $8,683 | -$8,749 |
| Pre-Tax Income | -$44,509 | -$21,671 | -$24,534 | -$122,481 |
| Tax Expense | $30 | -$3 | $45 | $64 |
| Net Income | -$44,539 | -$21,668 | -$24,579 | -$122,545 |
| % Margin | -7,652.7% | -31,864.7% | – | – |
| EPS | -1.57 | -4.08 | -8.06 | -56.61 |
| % Growth | 61.5% | 49.4% | 85.8% | – |
| EPS Diluted | -1.57 | -4.08 | -8.06 | -56.61 |
| Weighted Avg Shares Out | 28,398 | 5,314 | 3,051 | 2,165 |
| Weighted Avg Shares Out Dil | 28,398 | 5,314 | 3,051 | 2,165 |
| Supplemental Information | – | – | – | – |
| Interest Income | $249 | $138 | $0 | $0 |
| Interest Expense | $6,752 | $614 | $30 | $74 |
| Depreciation & Amortization | $1,638 | $1,123 | $497 | $459 |
| EBITDA | -$36,119 | -$19,934 | -$24,007 | -$121,948 |
| % Margin | -6,206% | -29,314.7% | – | – |